Header Logo

Connection

Usman Baber to Aspirin

Back to Details
This is a "connection" page, showing publications Usman Baber has written about Aspirin.
Usman Baber
Connection Strength
8.191
Aspirin
  1. The Role of Aspirin After High-Risk Percutaneous Coronary Intervention: The Ticagrelor with Aspirin or Alone in High-Risk Patients After Coronary Intervention Clinical Trial Experience. Interv Cardiol Clin. 2020 10; 9(4):489-498.
    View in: PubMed
    Score: 0.658
  2. Ticagrelor with or without Aspirin after PCI. Reply. N Engl J Med. 2020 03 12; 382(11):1076-1077.
    View in: PubMed
    Score: 0.633
  3. Ticagrelor With or Without Aspirin After PCI: The TWILIGHT Platelet Substudy. J Am Coll Cardiol. 2020 02 18; 75(6):578-586.
    View in: PubMed
    Score: 0.630
  4. Clinical trials in long-term antiplatelet therapies: focus on the role of aspirin. Curr Opin Cardiol. 2019 07; 34(4):315-322.
    View in: PubMed
    Score: 0.603
  5. Antiplatelet treatments: recent evidence from randomized controlled trials. Curr Opin Cardiol. 2017 Jul; 32(4):356-362.
    View in: PubMed
    Score: 0.525
  6. Ticagrelor with aspirin or alone in high-risk patients after coronary intervention: Rationale and design of the TWILIGHT study. Am Heart J. 2016 Dec; 182:125-134.
    View in: PubMed
    Score: 0.498
  7. Efficacy of modified dual antiplatelet therapy combined with warfarin following percutaneous coronary intervention with drug-eluting stents. J Invasive Cardiol. 2010 Feb; 22(2):80-3.
    View in: PubMed
    Score: 0.314
  8. Ticagrelor monotherapy versus ticagrelor plus aspirin in patients with chronic coronary syndrome and high ischaemic risk: a post hoc analysis of the TWILIGHT trial. EuroIntervention. 2025 May 16; 21(10):550-559.
    View in: PubMed
    Score: 0.226
  9. Antiplatelet Therapy for Patients Who Have Undergone Revascularization Within the Past Year: Which Agents and for How Long? Med Clin North Am. 2024 May; 108(3):539-551.
    View in: PubMed
    Score: 0.206
  10. Ticagrelor With or Without Aspirin in Chinese Patients Undergoing Percutaneous Coronary Intervention: A TWILIGHT China Substudy. Circ Cardiovasc Interv. 2022 04; 15(4):e009495.
    View in: PubMed
    Score: 0.182
  11. Sex Differences Among Patients With High Risk Receiving Ticagrelor With or Without Aspirin After Percutaneous Coronary Intervention: A Subgroup Analysis of the TWILIGHT Randomized Clinical Trial. JAMA Cardiol. 2021 09 01; 6(9):1032-1041.
    View in: PubMed
    Score: 0.175
  12. Extending the aspirin-free paradigm to patients with acute coronary syndrome: is it time to change guidelines? EuroIntervention. 2020 Oct 23; 16(8):620-622.
    View in: PubMed
    Score: 0.165
  13. Ticagrelor alone vs. ticagrelor plus aspirin following percutaneous coronary intervention in patients with non-ST-segment elevation acute coronary syndromes: TWILIGHT-ACS. Eur Heart J. 2020 10 01; 41(37):3533-3545.
    View in: PubMed
    Score: 0.164
  14. Duration of Dual Antiplatelet Therapy After PCI: How Short Can We Go? JACC Cardiovasc Interv. 2020 10 12; 13(19):2263-2265.
    View in: PubMed
    Score: 0.164
  15. Pharmacodynamic Effects of Vorapaxar in Prior Myocardial Infarction Patients Treated With Potent Oral P2Y12 Receptor Inhibitors With and Without Aspirin: Results of the VORA-PRATIC Study. J Am Heart Assoc. 2020 04 21; 9(8):e015865.
    View in: PubMed
    Score: 0.159
  16. Ticagrelor monotherapy beyond one month after PCI in ACS or stable CAD in elderly patients: a pre-specified analysis of the GLOBAL LEADERS trial. EuroIntervention. 2020 Apr 03; 15(18):e1605-e1614.
    View in: PubMed
    Score: 0.159
  17. Ticagrelor With or Without Aspirin in High-Risk Patients With Diabetes Mellitus Undergoing Percutaneous Coronary Intervention. J Am Coll Cardiol. 2020 05 19; 75(19):2403-2413.
    View in: PubMed
    Score: 0.159
  18. Ticagrelor With or Without Aspirin After Complex PCI. J Am Coll Cardiol. 2020 05 19; 75(19):2414-2424.
    View in: PubMed
    Score: 0.159
  19. Impact of high on-treatment platelet reactivity on outcomes following PCI in patients on hemodialysis: An ADAPT-DES substudy. Catheter Cardiovasc Interv. 2020 10 01; 96(4):793-801.
    View in: PubMed
    Score: 0.155
  20. Ticagrelor Monotherapy After Coronary Stenting: Is the GLASS Half Full or Half Empty? J Am Coll Cardiol. 2019 11 05; 74(18):2235-2237.
    View in: PubMed
    Score: 0.154
  21. Ticagrelor with or without Aspirin in High-Risk Patients after PCI. N Engl J Med. 2019 11 21; 381(21):2032-2042.
    View in: PubMed
    Score: 0.153
  22. Incidence, predictors, and outcomes of DAPT disruption due to non-compliance vs. bleeding after PCI: insights from the PARIS Registry. Clin Res Cardiol. 2019 Jun; 108(6):643-650.
    View in: PubMed
    Score: 0.146
  23. Aspirin-free strategies in cardiovascular disease and cardioembolic stroke prevention. Nat Rev Cardiol. 2018 08; 15(8):480-496.
    View in: PubMed
    Score: 0.141
  24. Causes, Timing, and Impact of Dual Antiplatelet Therapy Interruption for Surgery (from the Patterns of Non-adherence to Anti-platelet Regimens In Stented Patients Registry). Am J Cardiol. 2017 Sep 15; 120(6):904-910.
    View in: PubMed
    Score: 0.131
  25. Incidence, Patterns, and Associations Between Dual-Antiplatelet Therapy Cessation and Risk for Adverse Events Among Patients With and Without Diabetes Mellitus Receiving Drug-Eluting Stents: Results From the PARIS Registry. JACC Cardiovasc Interv. 2017 04 10; 10(7):645-654.
    View in: PubMed
    Score: 0.129
  26. Sex Differences in the Clinical Impact of High Platelet Reactivity After Percutaneous Coronary Intervention With Drug-Eluting Stents: Results From the ADAPT-DES Study (Assessment of Dual Antiplatelet Therapy With Drug-Eluting Stents). Circ Cardiovasc Interv. 2017 02; 10(2).
    View in: PubMed
    Score: 0.128
  27. Trial design: Rivaroxaban for the prevention of major cardiovascular events after transcatheter aortic valve replacement: Rationale and design of the GALILEO study. Am Heart J. 2017 Feb; 184:81-87.
    View in: PubMed
    Score: 0.125
  28. Impact of proton pump inhibitors and dual antiplatelet therapy cessation on outcomes following percutaneous coronary intervention: Results From the PARIS Registry. Catheter Cardiovasc Interv. 2017 Jun 01; 89(7):E217-E225.
    View in: PubMed
    Score: 0.124
  29. Coronary Thrombosis and Major Bleeding After PCI With Drug-Eluting Stents: Risk Scores From PARIS. J Am Coll Cardiol. 2016 May 17; 67(19):2224-2234.
    View in: PubMed
    Score: 0.121
  30. Antiplatelet therapy after drug-eluting stent implantation. J Cardiol. 2015 Feb; 65(2):98-104.
    View in: PubMed
    Score: 0.109
  31. Safety and efficacy of high- versus low-dose aspirin after primary percutaneous coronary intervention in ST-segment elevation myocardial infarction: the HORIZONS-AMI (Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction) trial. JACC Cardiovasc Interv. 2012 Dec; 5(12):1231-8.
    View in: PubMed
    Score: 0.096
  32. Dyspnea-Related Ticagrelor Discontinuation After Percutaneous?Coronary Intervention. JACC Cardiovasc Interv. 2023 10 23; 16(20):2514-2524.
    View in: PubMed
    Score: 0.051
  33. Bleeding and Ischemic Risks of Ticagrelor?Monotherapy After Coronary?Interventions. J Am Coll Cardiol. 2023 08 22; 82(8):687-700.
    View in: PubMed
    Score: 0.050
  34. Efficacy and safety of P2Y12 inhibitor monotherapy after complex PCI: a collaborative systematic review and meta-analysis. Eur Heart J Cardiovasc Pharmacother. 2023 04 10; 9(3):240-250.
    View in: PubMed
    Score: 0.049
  35. P2Y12 Inhibitor Monotherapy or Dual Antiplatelet Therapy After Complex Percutaneous Coronary Interventions. J Am Coll Cardiol. 2023 02 14; 81(6):537-552.
    View in: PubMed
    Score: 0.048
  36. Ticagrelor with and without aspirin in patients with a prior coronary artery bypass graft undergoing percutaneous coronary intervention: the TWILIGHT-CABG study. EuroIntervention. 2022 Dec 02; 18(11):e897-e909.
    View in: PubMed
    Score: 0.048
  37. Bleeding and Ischemic Outcomes With Ticagrelor Monotherapy According to Body Mass Index. JACC Cardiovasc Interv. 2022 10 10; 15(19):1948-1960.
    View in: PubMed
    Score: 0.047
  38. Ticagrelor monotherapy after PCI in patients with concomitant diabetes mellitus and chronic kidney disease: TWILIGHT DM-CKD. Eur Heart J Cardiovasc Pharmacother. 2022 Sep 29; 8(7):707-716.
    View in: PubMed
    Score: 0.047
  39. Aspirin-free strategies: a framework to reassess the role of dual antiplatelet therapy after percutaneous coronary intervention. Eur Heart J. 2021 07 15; 42(27):2710-2711.
    View in: PubMed
    Score: 0.043
  40. Impact of Age on the Safety and Efficacy of Ticagrelor Monotherapy in Patients Undergoing PCI. JACC Cardiovasc Interv. 2021 07 12; 14(13):1434-1446.
    View in: PubMed
    Score: 0.043
  41. Reply: P2Y12 Inhibitor-Based Monotherapy: Optimal Duration and Ideal Agent. J Am Coll Cardiol. 2020 09 08; 76(10):1274-1275.
    View in: PubMed
    Score: 0.041
  42. Geographical Variations in Patterns of DAPT Cessation and Two-Year PCI Outcomes: Insights from the PARIS Registry. Thromb Haemost. 2019 10; 119(10):1704-1711.
    View in: PubMed
    Score: 0.038
  43. Exome sequencing of extreme clopidogrel response phenotypes identifies B4GALT2 as a determinant of on-treatment platelet reactivity. Clin Pharmacol Ther. 2016 09; 100(3):287-94.
    View in: PubMed
    Score: 0.031
  44. Impact of Anemia on Platelet Reactivity and Ischemic and Bleeding Risk: From the Assessment of Dual Antiplatelet Therapy With Drug-Eluting Stents Study. Am J Cardiol. 2016 Jun 15; 117(12):1877-83.
    View in: PubMed
    Score: 0.030
  45. Duration of Dual Antiplatelet Therapy: A Systematic Review for the 2016 ACC/AHA Guideline Focused Update on Duration of Dual Antiplatelet Therapy in Patients With Coronary Artery Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2016 Sep 06; 134(10):e156-78.
    View in: PubMed
    Score: 0.030
  46. Ticagrelor reduces thrombus formation more than clopidogrel, even when co-administered with bivalirudin. Thromb Haemost. 2014 Nov; 112(5):1069-70.
    View in: PubMed
    Score: 0.027
  47. Should P2Y12 inhibitors be given for 12 months in acute coronary syndrome? Curr Opin Cardiol. 2014 Jul; 29(4):301-6.
    View in: PubMed
    Score: 0.027
  48. Current developments in dual antiplatelet therapy after stenting. Minerva Cardioangiol. 2014 Jun; 62(3):261-76.
    View in: PubMed
    Score: 0.026
  49. Safety of temporary and permanent suspension of antiplatelet therapy after drug eluting stent implantation in contemporary "real-world" practice. J Interv Cardiol. 2012 Oct; 25(5):482-92.
    View in: PubMed
    Score: 0.023
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.